Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lexicon Genetics is set to begin formal preclinical development for LX2931, a compound targeting autoimmune diseases, in order to prepare an investigational new drug application.
Subscribe to our email newsletter
LX2931 is a small molecule compound with potential application in the treatment of diseases such as multiple sclerosis and rheumatoid arthritis.
In preclinical research, LX2931 significantly reduced inflammatory response in mice and decreased lymphocyte counts in multiple species.
“We continue to anticipate that we will file an IND for LX1031 for irritable bowel syndrome later this year,” said Arthur Sands, Lexicon's president and CEO.
Lexicon is conducting preclinical research with lead small molecule compounds that inhibit LG267, a kinase that regulates immune cell activation and affects lymphocyte proliferation. This compound may also have applications in helping cancer patients recover from chemotherapy.